IDEXX Laboratories (IDXX) : Williams Jones Associates reduced its stake in IDEXX Laboratories by 0.69% during the most recent quarter end. The investment management company now holds a total of 653,018 shares of IDEXX Laboratories which is valued at $71,374,867 after selling 4,513 shares in IDEXX Laboratories , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.IDEXX Laboratories makes up approximately 2.12% of Williams Jones Associates’s portfolio.
Other Hedge Funds, Including , D.a. Davidson reduced its stake in IDXX by selling 80 shares or 25.0% in the most recent quarter. The Hedge Fund company now holds 240 shares of IDXX which is valued at $26,232. Usa Financial Portformulas Corp added IDXX to its portfolio by purchasing 11,211 company shares during the most recent quarter which is valued at $1,219,308. IDEXX Laboratories makes up approx 0.32% of Usa Financial Portformulas Corp’s portfolio.Mitsubishi Ufj Trust Banking Corp boosted its stake in IDXX in the latest quarter, The investment management firm added 1,995 additional shares and now holds a total of 179,090 shares of IDEXX Laboratories which is valued at $19,477,828. IDEXX Laboratories makes up approx 0.04% of Mitsubishi Ufj Trust Banking Corp’s portfolio.Tirschwell Loewy Inc reduced its stake in IDXX by selling 1,970 shares or 1.13% in the most recent quarter. The Hedge Fund company now holds 172,635 shares of IDXX which is valued at $19,159,032. IDEXX Laboratories makes up approx 3.29% of Tirschwell Loewy Inc’s portfolio. Navellier Associates Inc added IDXX to its portfolio by purchasing 41,696 company shares during the most recent quarter which is valued at $4,727,492. IDEXX Laboratories makes up approx 0.68% of Navellier Associates Inc’s portfolio.
IDEXX Laboratories opened for trading at $115.53 and hit $116.5 on the upside on Monday, eventually ending the session at $116.13, with a gain of 0.82% or 0.94 points. The heightened volatility saw the trading volume jump to 4,90,275 shares. Company has a market cap of $10,412 M.
On the company’s financial health, IDEXX Laboratories reported $0.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Nov 1, 2016. Analyst had a consensus of $0.60. The company had revenue of $448.31 million for the quarter, compared to analysts expectations of $449.10 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 EPS.
Many Wall Street Analysts have commented on IDEXX Laboratories. IDEXX Laboratories was Resumed by BofA/Merrill to “Neutral” on Sep 29, 2016.
IDEXX Laboratories Inc. develops manufactures and distributes products and provides services primarily for the companion animal veterinary livestock and poultry water testing and dairy markets. The Company sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include Companion Animal Group (CAG) Water Livestock Poultry and Dairy and Other. Its Products and services include point-of-care veterinary diagnostic products; veterinary reference laboratory diagnostic and consulting services; practice management systems and services and digital imaging systems; biological materials testing laboratory animal diagnostic instruments and services; diagnostic health-monitoring and food safety testing products for livestock poultry and dairy; products that test water for microbiological contaminants and point-of-care electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.